JPWO2021178488A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021178488A5 JPWO2021178488A5 JP2022552792A JP2022552792A JPWO2021178488A5 JP WO2021178488 A5 JPWO2021178488 A5 JP WO2021178488A5 JP 2022552792 A JP2022552792 A JP 2022552792A JP 2022552792 A JP2022552792 A JP 2022552792A JP WO2021178488 A5 JPWO2021178488 A5 JP WO2021178488A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- optionally
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 34
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical class 0.000 claims description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 239000001301 oxygen Chemical group 0.000 claims description 16
- 229910052717 sulfur Chemical group 0.000 claims description 16
- 239000011593 sulfur Chemical group 0.000 claims description 16
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- -1 substituted Chemical class 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
Description
本発明のいくつかの実施形態が記載されているが、本発明の化合物及び方法を利用する他の実施形態を提供するために基本的な実施例を変化させてもよいことは明らかである。したがって、本発明の範囲は、実施例として代表的に示された具体的な実施形態ではなく、明細書及び添付の特許請求の範囲によって定義されることが理解されよう。
本発明は、例えば、以下の項目を提供する。
(項目1)
式I:
の化合物、またはその薬学的に許容される塩であって、式中、
環Aが、フェニル、窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する5~6員の単環式ヘテロ芳香環、8~10員の二環式芳香族炭素環、または窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する8~10員の二環式ヘテロ芳香環から選択される、任意選択で置換される環であり、
L
1
が、結合、または任意選択で置換される二価の直鎖もしくは分岐状C
1-8
炭化水素鎖であり、前記炭化水素鎖の1、2、3、または4個のメチレン単位が、任意選択でかつ独立して、-O-、-S-、-N(R)-、-C(O)-、または-S(O)
2
-と置き換えられ、
R
2
が、ハロゲン、R、-OR、-SR、-C(O)R、-C(O)OR、-C(O)N(R)
2
、-S(O)
2
R、-S(O)
2
OR、または-S(O)
2
N(R)
2
であり、
L
2
が、結合、または任意選択で置換される二価の直鎖もしくは分岐状C
1-8
炭化水素鎖であり、前記炭化水素鎖の1、2、3、または4個のメチレン単位が、任意選択でかつ独立して、-O-、-S-、-N(R)-、-C(O)-、-S(O)
2
-、または-Cy-と置き換えられ、
R
3
が、-CN、-C(O)R、-C(O)OR、-C(O)N(R)
2
、-N(R)-C(O)-R、-N(R)-C(O)-OR、-S(O)
2
-N(R)
2
、-S(O)
2
-N(R)-C(O)R、-C(O)-N(R)-S(O)
2
R、-C(=NR)-N(R)
2
、-N(R)-C(=NR)-N(R)
2
、または窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する5~6員の単環式ヘテロ芳香環であり、
-Cy-が、フェニレン、窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する5~6員の単環式ヘテロ芳香環、3~6員の飽和もしくは部分的に不飽和の単環式炭素環、窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する3~6員の飽和もしくは部分的に不飽和の単環式複素環、8~10員の二環式芳香族炭素環、または窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する8~10員の二環式ヘテロ芳香環から選択される、任意選択で置換される二価の環であり、
Rが、水素、任意選択で置換される-C
1-6
脂肪族であるか、あるいはフェニル、窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する5~6員の単環式ヘテロ芳香環、3~6員の飽和もしくは部分的に不飽和の単環式炭素環、または窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する3~6員の飽和もしくは部分的に不飽和の単環式複素環から選択される、任意選択で置換される環である、
前記化合物、またはその薬学的に許容される塩。
(項目2)
環Aが、任意選択で置換されるフェニルである、項目1に記載の化合物。
(項目3)
環Aが、
であり、式中、各R
1
が独立して、ハロゲン、R、-N(R)
2
、-OR、-SR、-C(O)OR、または-S(O)
2
Rであり、nが、0、1、2、3、4、または5である、項目2に記載の化合物。
(項目4)
環Aが、
であり、式中、R
11
及びR
12
の各々が独立して、ハロゲン、R、-N(R)
2
、-OR、-SR、-C(O)OR、または-S(O)
2
Rである、項目2に記載の化合物。
(項目5)
R
12
のうちの少なくとも1つが、水素ではない、項目4に記載の化合物。
(項目6)
L
1
が、結合である、先行項目のいずれか1項に記載の化合物。
(項目7)
R
2
が、水素ではない、先行項目のいずれか1項に記載の化合物。
(項目8)
R
2
が、任意選択で置換される-C
1-6
脂肪族である、項目7に記載の化合物。
(項目9)
R
2
が、H、
である、先行項目のいずれか1項に記載の化合物。
(項目10)
L
2
が、カルボキサミド、またはスルホンアミド、またはジアゾール部分を介してはチアゾール部分に結合しない、先行項目のいずれか1項に記載の化合物。
(項目11)
L
2
が、
である、項目10に記載の化合物。
(項目12)
R
3
が、-COOH、-CN、
である、先行項目のいずれか1項に記載の化合物。
(項目13)
Rが、水素、または任意選択で置換される-C
1-6
脂肪族である、先行項目のいずれか1項に記載の化合物。
(項目14)
前記化合物が、式II:
のもの、またはその薬学的に許容される塩であり、式中、R
1
が独立して、ハロゲン、R、-N(R)
2
、-OR、-SR、-C(O)OR、または-S(O)
2
Rであり、nが、0、1、2、3、4、または5である、項目1に記載の化合物。
(項目15)
前記化合物が、式II-a~II-d:
のもの、またはその薬学的に許容される塩であり、式中、R
11
及びR
12
の各々が独立して、ハロゲン、R、-N(R)
2
、-OR、-SR、-C(O)OR、または-S(O)
2
Rである、項目1に記載の化合物。
(項目16)
前記化合物が、式III:
のもの、またはその薬学的に許容される塩であり、式中、R
1
が独立して、ハロゲン、R、-N(R)
2
、-OR、-SR、-C(O)OR、または-S(O)
2
Rであり、nが、0、1、2、3、4、または5である、項目1に記載の化合物。
(項目17)
前記化合物が、式III-a~III-d:
のもの、またはその薬学的に許容される塩であり、式中、R
11
及びR
12
の各々が独立して、ハロゲン、R、-N(R)
2
、-OR、-SR、-C(O)OR、または-S(O)
2
Rである、項目1に記載の化合物。
(項目18)
前記化合物が、式IV:
のもの、またはその薬学的に許容される塩であり、式中、R
1
が独立して、ハロゲン、R、-N(R)
2
、-OR、-SR、-C(O)OR、または-S(O)
2
Rであり、nが、0、1、2、3、4、または5である、項目1に記載の化合物。
(項目19)
前記化合物が、式IV-a~IV-d:
のもの、またはその薬学的に許容される塩であり、式中、R
11
及びR
12
の各々が独立して、ハロゲン、R、-N(R)
2
、-OR、-SR、-C(O)OR、または-S(O)
2
Rである、項目1に記載の化合物。
(項目20)
前記化合物が、式V:
のもの、またはその薬学的に許容される塩であり、式中、R
1
が独立して、ハロゲン、R、-N(R)
2
、-OR、-SR、-C(O)OR、または-S(O)
2
Rであり、nが、0、1、2、3、4、または5である、項目1に記載の化合物。
(項目21)
前記化合物が、式V-a~V-d:
のもの、またはその薬学的に許容される塩であり、式中、R
11
及びR
12
の各々が独立して、ハロゲン、R、-N(R)
2
、-OR、-SR、-C(O)OR、または-S(O)
2
Rである、項目1に記載の化合物。
(項目22)
前記化合物が、式VI:
のもの、またはその薬学的に許容される塩であり、式中、R
1
が独立して、ハロゲン、R、-N(R)
2
、-OR、-SR、-C(O)OR、または-S(O)
2
Rであり、nが、0、1、2、3、4、または5である、項目1に記載の化合物。
(項目23)
前記化合物が、式VI-a~VI-d:
のもの、またはその薬学的に許容される塩であり、式中、R
11
及びR
12
の各々が独立して、ハロゲン、R、-N(R)
2
、-OR、-SR、-C(O)OR、または-S(O)
2
Rである、項目1に記載の化合物。
(項目24)
前記化合物が、式VII:
のもの、またはその薬学的に許容される塩であり、式中、R
1
が独立して、ハロゲン、R、-N(R)
2
、-OR、-SR、-C(O)OR、または-S(O)
2
Rであり、nが、0、1、2、3、4、または5である、項目1に記載の化合物。
(項目25)
前記化合物が、式VII-a~VII-d:
のもの、またはその薬学的に許容される塩であり、式中、R
11
及びR
12
の各々が独立して、ハロゲン、R、-N(R)
2
、-OR、-SR、-C(O)OR、または-S(O)
2
Rである、項目1に記載の化合物。
(項目26)
表1から選択される、項目1に記載の化合物、またはその薬学的に許容される塩。
(項目27)
項目1~26のいずれか1項に記載の化合物、またはその薬学的に許容される塩と、薬学的に許容される担体、アジュバント、またはビヒクルとを含む、薬学的組成物。
(項目28)
患者においてがんを治療するための方法であって、前記患者に、項目1~27のいずれか1項に記載の化合物、またはその薬学的に許容される塩を投与することを含む、前記方法。
While several embodiments of the invention have been described, it will be obvious that the basic examples may be varied to provide other embodiments utilizing the compounds and methods of the invention. It is therefore understood that the scope of the invention is defined by the specification and appended claims, and not by the specific embodiments shown by way of example.
The present invention provides, for example, the following items.
(Item 1)
Formula I:
or a pharmaceutically acceptable salt thereof, in which:
5- to 6-membered monocyclic heteroaromatic ring, 8- to 10-membered bicyclic aromatic ring in which ring A has 1 to 4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur; an optionally substituted ring selected from a carbocycle or an 8-10 membered bicyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; can be,
L 1 is a bond or an optionally substituted divalent straight or branched C 1-8 hydrocarbon chain, and 1, 2, 3, or 4 methylene units of the hydrocarbon chain are optionally and independently replaced with -O-, -S-, -N(R)-, -C(O)-, or -S(O) 2 -,
R 2 is halogen, R, -OR, -SR, -C(O)R, -C(O)OR, -C(O)N(R) 2 , -S(O) 2 R, -S( O) 2 OR, or -S(O) 2 N(R) 2 ,
L 2 is a bond or an optionally substituted divalent straight or branched C 1-8 hydrocarbon chain, and 1, 2, 3, or 4 methylene units of said hydrocarbon chain are optionally and independently replaced with -O-, -S-, -N(R)-, -C(O)-, -S(O) 2 -, or -Cy-,
R 3 is -CN, -C(O)R, -C(O)OR, -C(O)N(R) 2 , -N(R)-C(O)-R, -N(R) -C(O)-OR, -S(O) 2 -N(R) 2 , -S(O) 2 -N(R)-C(O)R, -C(O)-N(R)- independently selected from S(O) 2 R, -C(=NR)-N(R) 2 , -N(R)-C(=NR)-N(R) 2 , or nitrogen, oxygen, and sulfur a 5- to 6-membered monocyclic heteroaromatic ring having 1 to 4 heteroatoms,
-Cy- is a 5- to 6-membered monocyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from phenylene, nitrogen, oxygen, and sulfur, a 3- to 6-membered saturated or partially a 3- to 6-membered saturated or partially unsaturated monocyclic heterocycle having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; , an 8- to 10-membered bicyclic aromatic carbocycle, or an 8- to 10-membered bicyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. an optionally substituted divalent ring,
5-6 where R is hydrogen, optionally substituted -C 1-6 aliphatic, or has 1 to 4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur; a membered monocyclic heteroaromatic ring, a 3 to 6 membered saturated or partially unsaturated monocyclic carbocycle, or 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. is an optionally substituted ring selected from 3- to 6-membered saturated or partially unsaturated monocyclic heterocycles having
The above compound or a pharmaceutically acceptable salt thereof.
(Item 2)
A compound according to item 1, wherein Ring A is optionally substituted phenyl.
(Item 3)
Ring A is
, where each R 1 is independently halogen, R, -N(R) 2 , -OR, -SR, -C(O)OR, or -S(O) 2 R, and n is 0, 1, 2, 3, 4, or 5.
(Item 4)
Ring A is
and in the formula, each of R 11 and R 12 is independently halogen, R, -N(R) 2 , -OR, -SR, -C(O)OR, or -S(O) 2 R The compound according to item 2, which is
(Item 5)
A compound according to item 4, wherein at least one of R 12 is not hydrogen.
(Item 6)
A compound according to any one of the preceding items, wherein L 1 is a bond.
(Item 7)
A compound according to any one of the preceding items, wherein R 2 is not hydrogen.
(Item 8)
A compound according to item 7, wherein R 2 is an optionally substituted -C 1-6 aliphatic.
(Item 9)
R2 is H,
A compound according to any one of the preceding items.
(Item 10)
A compound according to any one of the preceding items, wherein L 2 is not attached to the thiazole moiety via a carboxamide, or sulfonamide, or diazole moiety.
(Item 11)
L 2 is
The compound according to item 10, which is
(Item 12)
R 3 is -COOH, -CN,
A compound according to any one of the preceding items.
(Item 13)
A compound according to any one of the preceding items, wherein R is hydrogen or an optionally substituted -C 1-6 aliphatic.
(Item 14)
The compound has formula II:
or a pharmaceutically acceptable salt thereof, in which R 1 is independently halogen, R, -N(R) 2 , -OR, -SR, -C(O)OR, or -S(O) 2 R and n is 0, 1, 2, 3, 4, or 5.
(Item 15)
The compound has formulas II-a to II-d:
or a pharmaceutically acceptable salt thereof, in which each of R 11 and R 12 independently represents halogen, R, -N(R) 2 , -OR, -SR, -C( The compound according to item 1, which is O)OR, or -S(O) 2 R.
(Item 16)
The compound has formula III:
or a pharmaceutically acceptable salt thereof, in which R 1 is independently halogen, R, -N(R) 2 , -OR, -SR, -C(O)OR, or -S(O) 2 R and n is 0, 1, 2, 3, 4, or 5.
(Item 17)
The compound has formulas III-a to III-d:
or a pharmaceutically acceptable salt thereof, in which each of R 11 and R 12 independently represents halogen, R, -N(R) 2 , -OR, -SR, -C( The compound according to item 1, which is O)OR, or -S(O) 2 R.
(Item 18)
The compound has formula IV:
or a pharmaceutically acceptable salt thereof, in which R 1 is independently halogen, R, -N(R) 2 , -OR, -SR, -C(O)OR, or -S(O) 2 R and n is 0, 1, 2, 3, 4, or 5.
(Item 19)
The compound has formulas IV-a to IV-d:
or a pharmaceutically acceptable salt thereof, in which each of R 11 and R 12 independently represents halogen, R, -N(R) 2 , -OR, -SR, -C( The compound according to item 1, which is O)OR, or -S(O) 2 R.
(Item 20)
The compound has formula V:
or a pharmaceutically acceptable salt thereof, in which R 1 is independently halogen, R, -N(R) 2 , -OR, -SR, -C(O)OR, or -S(O) 2 R and n is 0, 1, 2, 3, 4, or 5.
(Item 21)
The compound has formulas V-a to V-d:
or a pharmaceutically acceptable salt thereof, in which each of R 11 and R 12 independently represents halogen, R, -N(R) 2 , -OR, -SR, -C( The compound according to item 1, which is O)OR, or -S(O) 2 R.
(Item 22)
The compound has formula VI:
or a pharmaceutically acceptable salt thereof, in which R 1 is independently halogen, R, -N(R) 2 , -OR, -SR, -C(O)OR, or -S(O) 2 R and n is 0, 1, 2, 3, 4, or 5.
(Item 23)
The compound has formulas VI-a to VI-d:
or a pharmaceutically acceptable salt thereof, in which each of R 11 and R 12 independently represents halogen, R, -N(R) 2 , -OR, -SR, -C( The compound according to item 1, which is O)OR, or -S(O) 2 R.
(Item 24)
The compound has formula VII:
or a pharmaceutically acceptable salt thereof, in which R 1 is independently halogen, R, -N(R) 2 , -OR, -SR, -C(O)OR, or -S(O) 2 R and n is 0, 1, 2, 3, 4, or 5.
(Item 25)
The compound has formulas VII-a to VII-d:
or a pharmaceutically acceptable salt thereof, in which each of R 11 and R 12 independently represents halogen, R, -N(R) 2 , -OR, -SR, -C( The compound according to item 1, which is O)OR, or -S(O) 2 R.
(Item 26)
A compound according to item 1, or a pharmaceutically acceptable salt thereof, selected from Table 1.
(Item 27)
A pharmaceutical composition comprising a compound according to any one of items 1 to 26, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
(Item 28)
A method for treating cancer in a patient, the method comprising administering to the patient a compound according to any one of items 1 to 27, or a pharmaceutically acceptable salt thereof. .
Claims (16)
環Aが、フェニル、窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する5~6員の単環式ヘテロ芳香環、8~10員の二環式芳香族炭素環、または窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する8~10員の二環式ヘテロ芳香環から選択される、任意選択で置換される環であり、
L1が、結合、または任意選択で置換される二価の直鎖もしくは分岐状C1-8炭化水素鎖であり、前記炭化水素鎖の1、2、3、または4個のメチレン単位が、任意選択でかつ独立して、-O-、-S-、-N(R)-、-C(O)-、または-S(O)2-と置き換えられ、
R2が、ハロゲン、R、-OR、-SR、-C(O)R、-C(O)OR、-C(O)N(R)2、-S(O)2R、-S(O)2OR、または-S(O)2N(R)2であり、
L2が、結合、または任意選択で置換される二価の直鎖もしくは分岐状C1-8炭化水素鎖であり、前記炭化水素鎖の1、2、3、または4個のメチレン単位が、任意選択でかつ独立して、-O-、-S-、-N(R)-、-C(O)-、-S(O)2-、または-Cy-と置き換えられ、
R3が、-CN、-C(O)R、-C(O)OR、-C(O)N(R)2、-N(R)-C(O)-R、-N(R)-C(O)-OR、-S(O)2-N(R)2、-S(O)2-N(R)-C(O)R、-C(O)-N(R)-S(O)2R、-C(=NR)-N(R)2、-N(R)-C(=NR)-N(R)2、または窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する5~6員の単環式ヘテロ芳香環であり、
-Cy-が、フェニレン、窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する5~6員の単環式ヘテロ芳香環、3~6員の飽和もしくは部分的に不飽和の単環式炭素環、窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する3~6員の飽和もしくは部分的に不飽和の単環式複素環、8~10員の二環式芳香族炭素環、または窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する8~10員の二環式ヘテロ芳香環から選択される、任意選択で置換される二価の環であり、
Rが、水素、任意選択で置換される-C1-6脂肪族であるか、あるいはフェニル、窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する5~6員の単環式ヘテロ芳香環、3~6員の飽和もしくは部分的に不飽和の単環式炭素環、または窒素、酸素、及び硫黄から独立して選択される1~4個のヘテロ原子を有する3~6員の飽和もしくは部分的に不飽和の単環式複素環から選択される、任意選択で置換される環である、
前記化合物、またはその薬学的に許容される塩。 Formula I:
5- to 6-membered monocyclic heteroaromatic ring, 8- to 10-membered bicyclic aromatic ring in which ring A has 1 to 4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur; an optionally substituted ring selected from a carbocycle or an 8-10 membered bicyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; can be,
L 1 is a bond or an optionally substituted divalent straight or branched C 1-8 hydrocarbon chain, and 1, 2, 3, or 4 methylene units of the hydrocarbon chain are optionally and independently replaced with -O-, -S-, -N(R)-, -C(O)-, or -S(O) 2 -,
R 2 is halogen, R, -OR, -SR, -C(O)R, -C(O)OR, -C(O)N(R) 2 , -S(O) 2 R, -S( O) 2 OR, or -S(O) 2 N(R) 2 ,
L 2 is a bond or an optionally substituted divalent straight or branched C 1-8 hydrocarbon chain, and 1, 2, 3, or 4 methylene units of said hydrocarbon chain are optionally and independently replaced with -O-, -S-, -N(R)-, -C(O)-, -S(O) 2 -, or -Cy-,
R 3 is -CN, -C(O)R, -C(O)OR, -C(O)N(R) 2 , -N(R)-C(O)-R, -N(R) -C(O)-OR, -S(O) 2 -N(R) 2 , -S(O) 2 -N(R)-C(O)R, -C(O)-N(R)- independently selected from S(O) 2 R, -C(=NR)-N(R) 2 , -N(R)-C(=NR)-N(R) 2 , or nitrogen, oxygen, and sulfur a 5- to 6-membered monocyclic heteroaromatic ring having 1 to 4 heteroatoms,
-Cy- is a 5- to 6-membered monocyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from phenylene, nitrogen, oxygen, and sulfur, a 3- to 6-membered saturated or partially a 3- to 6-membered saturated or partially unsaturated monocyclic heterocycle having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; , an 8- to 10-membered bicyclic aromatic carbocycle, or an 8- to 10-membered bicyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. an optionally substituted divalent ring,
5-6 where R is hydrogen, optionally substituted -C 1-6 aliphatic, or has 1 to 4 heteroatoms independently selected from phenyl, nitrogen, oxygen, and sulfur; a membered monocyclic heteroaromatic ring, a 3 to 6 membered saturated or partially unsaturated monocyclic carbocycle, or 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. is an optionally substituted ring selected from 3- to 6-membered saturated or partially unsaturated monocyclic heterocycles having
The above compound or a pharmaceutically acceptable salt thereof.
環Aが、
であり、式中、各R 1 が独立して、ハロゲン、R、-N(R) 2 、-OR、-SR、-C(O)OR、または-S(O) 2 Rであり、nが、0、1、2、3、4、または5であり、さらに任意選択で
環Aが、
であり、式中、R 11 及びR 12 の各々が独立して、ハロゲン、R、-N(R) 2 、-OR、-SR、-C(O)OR、または-S(O) 2 Rであり、任意選択で
R 12 のうちの少なくとも1つが、水素ではない、請求項1に記載の化合物。 Ring A is optionally substituted phenyl, optionally
Ring A is
, where each R 1 is independently halogen, R, -N(R) 2 , -OR, -SR, -C(O)OR, or -S(O) 2 R, and n is 0, 1, 2, 3, 4, or 5, and optionally
Ring A is
and in the formula, each of R 11 and R 12 is independently halogen, R, -N(R) 2 , -OR, -SR, -C(O)OR, or -S(O) 2 R and optionally
2. A compound according to claim 1, wherein at least one of R12 is not hydrogen .
R 2 が、任意選択で置換される-C 1-6 脂肪族であり、さらに任意選択で
R 2 が、H、
である、請求項1~3のいずれか1項に記載の化合物。 R 2 is not hydrogen and optionally
R 2 is an optionally substituted -C 1-6 aliphatic, further optionally
R 2 is H,
The compound according to any one of claims 1 to 3 , which is
L 2 が、
である、請求項1~4のいずれか1項に記載の化合物。 L 2 is not attached to the thiazole moiety through a carboxamide, or sulfonamide, or diazole moiety, and is optionally
L 2 is
The compound according to any one of claims 1 to 4 , which is
前記化合物が、式II-a~II-d:
のもの、またはその薬学的に許容される塩であり、式中、R 11 及びR 12 の各々が独立して、ハロゲン、R、-N(R) 2 、-OR、-SR、-C(O)OR、または-S(O) 2 Rである、請求項1に記載の化合物。 The compound has formula II:
The compound has formulas II-a to II-d:
or a pharmaceutically acceptable salt thereof, in which each of R 11 and R 12 independently represents halogen, R, -N(R) 2 , -OR, -SR, -C( 2. The compound according to claim 1, which is O)OR, or -S(O) 2R .
前記化合物が、式III-a~III-d:
のもの、またはその薬学的に許容される塩であり、式中、R 11 及びR 12 の各々が独立して、ハロゲン、R、-N(R) 2 、-OR、-SR、-C(O)OR、または-S(O) 2 Rである、請求項1に記載の化合物。 The compound has formula III:
The compound has formulas III-a to III-d:
or a pharmaceutically acceptable salt thereof, in which each of R 11 and R 12 independently represents halogen, R, -N(R) 2 , -OR, -SR, -C( 2. The compound according to claim 1, which is O)OR, or -S(O) 2R .
前記化合物が、式IV-a~IV-d:
のもの、またはその薬学的に許容される塩であり、式中、R 11 及びR 12 の各々が独立して、ハロゲン、R、-N(R) 2 、-OR、-SR、-C(O)OR、または-S(O) 2 Rである、請求項1に記載の化合物。 The compound has formula IV:
The compound has formulas IV-a to IV-d:
or a pharmaceutically acceptable salt thereof, in which each of R 11 and R 12 independently represents halogen, R, -N(R) 2 , -OR, -SR, -C( 2. The compound according to claim 1, which is O)OR, or -S(O) 2R .
前記化合物が、式V-a~V-d:
のもの、またはその薬学的に許容される塩であり、式中、R 11 及びR 12 の各々が独立して、ハロゲン、R、-N(R) 2 、-OR、-SR、-C(O)OR、または-S(O) 2 Rである、請求項1に記載の化合物。 The compound has formula V:
The compound has formulas V-a to V-d:
or a pharmaceutically acceptable salt thereof, in which each of R 11 and R 12 independently represents halogen, R, -N(R) 2 , -OR, -SR, -C( 2. The compound according to claim 1, which is O)OR, or -S(O) 2R .
前記化合物が、式VI-a~VI-d:
のもの、またはその薬学的に許容される塩であり、式中、R 11 及びR 12 の各々が独立して、ハロゲン、R、-N(R) 2 、-OR、-SR、-C(O)OR、または-S(O) 2 Rである、請求項1に記載の化合物。 The compound has formula VI:
The compound has formulas VI-a to VI-d:
or a pharmaceutically acceptable salt thereof, in which each of R 11 and R 12 independently represents halogen, R, -N(R) 2 , -OR, -SR, -C( 2. The compound according to claim 1, which is O)OR, or -S(O) 2R .
前記化合物が、式VII-a~VII-d:
のもの、またはその薬学的に許容される塩であり、式中、R 11 及びR 12 の各々が独立して、ハロゲン、R、-N(R) 2 、-OR、-SR、-C(O)OR、または-S(O) 2 Rである、請求項1に記載の化合物。 The compound has formula VII:
The compound has formulas VII-a to VII-d:
or a pharmaceutically acceptable salt thereof, in which each of R 11 and R 12 independently represents halogen, R, -N(R) 2 , -OR, -SR, -C( 2. The compound according to claim 1, which is O)OR, or -S(O) 2R .
A composition for treating cancer in a patient , said composition comprising a compound according to any one of claims 1 to 14 , or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062984543P | 2020-03-03 | 2020-03-03 | |
US62/984,543 | 2020-03-03 | ||
PCT/US2021/020597 WO2021178488A1 (en) | 2020-03-03 | 2021-03-03 | Eif4e inhibitors and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023515888A JP2023515888A (en) | 2023-04-14 |
JPWO2021178488A5 true JPWO2021178488A5 (en) | 2024-03-12 |
Family
ID=75173469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022552792A Pending JP2023515888A (en) | 2020-03-03 | 2021-03-03 | eIF4E inhibitors and uses thereof |
Country Status (15)
Country | Link |
---|---|
US (2) | US11753403B2 (en) |
EP (1) | EP4114529A1 (en) |
JP (1) | JP2023515888A (en) |
KR (1) | KR20220164706A (en) |
CN (1) | CN115515685A (en) |
AR (1) | AR121506A1 (en) |
AU (1) | AU2021230289A1 (en) |
BR (1) | BR112022017727A2 (en) |
CA (1) | CA3170411A1 (en) |
CL (1) | CL2022002402A1 (en) |
CO (1) | CO2022012594A2 (en) |
IL (1) | IL296139A (en) |
MX (1) | MX2022010944A (en) |
TW (1) | TW202146393A (en) |
WO (1) | WO2021178488A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220164706A (en) | 2020-03-03 | 2022-12-13 | 피아이씨 테라퓨틱스 인코포레이티드 | EIF4E Inhibitors and Uses Thereof |
JP2024502083A (en) * | 2020-12-31 | 2024-01-17 | 清華大学 | Pyridin-2-amine derivatives, pharmaceutical compositions and uses thereof |
IL310924A (en) * | 2021-08-25 | 2024-04-01 | Pic Therapeutics Inc | Eif4e inhibitors and uses thereof |
WO2023028238A1 (en) * | 2021-08-25 | 2023-03-02 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
GB2615307A (en) * | 2022-01-28 | 2023-08-09 | Adorx Therapeutics Ltd | Antagonist compounds |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (en) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Ring gap magnet system |
DE4124942A1 (en) | 1991-07-27 | 1993-01-28 | Thomae Gmbh Dr K | 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING SUCH COMPOUNDS |
JPH07149745A (en) | 1993-11-30 | 1995-06-13 | Hisamitsu Pharmaceut Co Inc | New 2-aminothiazole derivative |
AU3998400A (en) * | 1999-02-09 | 2000-08-29 | 3-Dimensional Pharmaceuticals, Inc. | Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor |
WO2001042246A2 (en) | 1999-12-10 | 2001-06-14 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
DE60217322T2 (en) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclic compound and antitumor agent containing it as an active ingredient |
CA2474322A1 (en) * | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
IL166718A0 (en) | 2002-08-14 | 2006-01-15 | Atugen Ag | Further use of protein kinase n beta |
EA012240B1 (en) | 2003-04-03 | 2009-08-28 | Семафор Фармасьютикалз, Инк. | Pi-3 kinase inhibitor prodrugs |
JP4980715B2 (en) | 2003-05-30 | 2012-07-18 | ジェミン エックス ファーマシューティカルズ カナダ インコーポレイテッド | Tricyclic heterocyclic compounds, compositions and methods for treating cancer or viral diseases |
EP2371835A1 (en) | 2003-07-03 | 2011-10-05 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
EP1753735A1 (en) | 2004-04-20 | 2007-02-21 | Transtech Pharma, Inc. | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
US7932260B2 (en) | 2004-05-13 | 2011-04-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
TWI380996B (en) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | Anti-ox40l antibodies |
ATE451381T1 (en) | 2005-01-19 | 2009-12-15 | Rigel Pharmaceuticals Inc | PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND USES THEREOF |
JP5225691B2 (en) * | 2005-01-21 | 2013-07-03 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Regulation of protein synthesis |
ES2432091T5 (en) | 2005-03-25 | 2022-03-18 | Gitr Inc | GITR binding molecules and uses thereof |
PT1888550E (en) | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Apoptosis promoters |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CN104356236B (en) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | Human monoclonal antibodies to programmed death ligand 1(PD-L1) |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
JP5270353B2 (en) | 2005-10-07 | 2013-08-21 | エクセリクシス, インク. | Phosphatidylinositol 3-kinase inhibitor and method of use thereof |
PT1951684T (en) | 2005-11-01 | 2016-10-13 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
TWI468162B (en) | 2005-12-13 | 2015-01-11 | 英塞特公司 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
CA2682189C (en) * | 2006-04-07 | 2015-12-08 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
CL2007001165A1 (en) | 2006-04-26 | 2008-01-25 | Hoffmann La Roche | 2- (1h-indazol-4-yl) -6- (4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-thieno [3,2-d] pyrimidine; preparation procedure; pharmaceutical composition; process of preparing said composition; pharmaceutical kit; and use to treat diseases such as cancer, immune disorders and cardiovascular diseases. |
BRPI0622054B8 (en) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | compound and pharmaceutical composition |
KR101737753B1 (en) | 2007-03-12 | 2017-05-18 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | Phenyl amino pyrimidine compounds and uses thereof |
US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
PE20090717A1 (en) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS |
ES2591281T3 (en) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Combination therapies that employ GITR binding molecules |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
EP2227233B1 (en) | 2007-11-30 | 2013-02-13 | Newlink Genetics | Ido inhibitors |
ES2602577T3 (en) | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
JP2011523616A (en) | 2008-05-29 | 2011-08-18 | サン−ゴバン サントル ドゥ ルシェルシェ エ デトゥードゥ ユーロペン | Porous structure containing aluminum titanate |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
WO2010025142A1 (en) | 2008-08-29 | 2010-03-04 | Transtech Pharma, Inc. | Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use |
PE20120341A1 (en) | 2008-12-09 | 2012-04-24 | Genentech Inc | ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION |
GB0900388D0 (en) * | 2009-01-12 | 2009-02-11 | Addex Pharmaceuticals Sa | New compounds |
US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
ES2722300T3 (en) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Antibodies that preferentially bind to extracellular domain 4 of CSF1R and its use |
WO2011140249A2 (en) | 2010-05-04 | 2011-11-10 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
CN106220739A (en) | 2010-12-09 | 2016-12-14 | 宾夕法尼亚大学董事会 | The purposes of the T cell treatment cancer that Chimeric antigen receptor is modified |
NO2694640T3 (en) | 2011-04-15 | 2018-03-17 | ||
CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
US9073881B2 (en) * | 2011-09-23 | 2015-07-07 | Hoffmann-La Roche Inc. | Benzoic acid derivatives |
LT2785375T (en) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
CN104159921B (en) | 2011-12-15 | 2018-05-04 | 霍夫曼-拉罗奇有限公司 | Antibody for people CSF-1R and application thereof |
RU2014136332A (en) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | COMPOSITIONS AND METHODS OF APPLICATION OF CSF1R INHIBITORS |
AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
RU2670743C9 (en) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
UY34887A (en) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
RU2718751C2 (en) | 2012-08-31 | 2020-04-14 | Файв Прайм Терапьютикс, Инк. | Methods of treating pathological conditions with antibodies which bind to the colony-stimulating factor 1 receptor (csf1r) |
WO2015050984A1 (en) * | 2013-10-01 | 2015-04-09 | New York University | Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof |
CA3025492A1 (en) * | 2015-06-01 | 2016-12-08 | Bantam Pharmaceutical, Llc | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto |
JP2022500499A (en) * | 2018-09-07 | 2022-01-04 | ピク セラピューティクス, インコーポレイテッド | EIF4E Inhibitors and Their Use |
CN109456279B (en) * | 2018-10-12 | 2022-11-22 | 南华大学 | Thiazolylaminobenzamide acetate derivatives and uses thereof |
CN109232467B (en) * | 2018-10-12 | 2022-11-25 | 南华大学 | Thiazole aminobenzoic acid derivative and application thereof |
CN109320473B (en) * | 2018-10-17 | 2022-11-22 | 南华大学 | Thiazolylaminobenzamide acetic acid derivatives and uses thereof |
KR20220164706A (en) | 2020-03-03 | 2022-12-13 | 피아이씨 테라퓨틱스 인코포레이티드 | EIF4E Inhibitors and Uses Thereof |
-
2021
- 2021-03-03 KR KR1020227033872A patent/KR20220164706A/en unknown
- 2021-03-03 MX MX2022010944A patent/MX2022010944A/en unknown
- 2021-03-03 CN CN202180032438.6A patent/CN115515685A/en active Pending
- 2021-03-03 TW TW110107613A patent/TW202146393A/en unknown
- 2021-03-03 BR BR112022017727A patent/BR112022017727A2/en unknown
- 2021-03-03 EP EP21714071.4A patent/EP4114529A1/en active Pending
- 2021-03-03 WO PCT/US2021/020597 patent/WO2021178488A1/en unknown
- 2021-03-03 JP JP2022552792A patent/JP2023515888A/en active Pending
- 2021-03-03 AR ARP210100559A patent/AR121506A1/en unknown
- 2021-03-03 IL IL296139A patent/IL296139A/en unknown
- 2021-03-03 CA CA3170411A patent/CA3170411A1/en active Pending
- 2021-03-03 US US17/191,072 patent/US11753403B2/en active Active
- 2021-03-03 AU AU2021230289A patent/AU2021230289A1/en active Pending
-
2022
- 2022-09-02 CL CL2022002402A patent/CL2022002402A1/en unknown
- 2022-09-02 CO CONC2022/0012594A patent/CO2022012594A2/en unknown
-
2023
- 2023-06-15 US US18/210,306 patent/US20230399322A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI354666B (en) | Heterocyclic aspartyl protease inhibitors | |
FI112222B (en) | A process for the preparation of novel therapeutically useful furanone derivatives | |
AU720615B2 (en) | Bis-sulfonomides hydroxamic acids as MMP inhibitors | |
RU2007124329A (en) | 5-HYDROXYBENZENESOTIAZOLE DERIVATIVES AS β2 ADRENORECEPTOR AGONISTS | |
SE8303824D0 (en) | N-IMIDAZOLYL DERIVATIVES OF BICYCLIC COMPOUNDS AND PROCESS FOR THEIR PREPARATION | |
FR2542740A1 (en) | THIAZOLIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
JPWO2020243415A5 (en) | ||
RU94045897A (en) | Indole derivatives as 5-hti-agonists, pharmaceutical composition and treatment method | |
CA2075017A1 (en) | (isoquinolein-5-yl) sulfonamides, process for their prepara tion and pharmaceutical compositions containing them | |
JPWO2021178488A5 (en) | ||
RU94040914A (en) | Derivatives of indole showing affinity to 5-ht1 receptor, pharmaceutical composition and treatment method | |
KR910004569A (en) | (Quinolin-2-yl-methoxy) phenylacetic acid derivatives with cyclic substituents | |
JP2010520299A (en) | Method for treating cognitive impairment using 3-aryl-3-hydroxy-2-amino-propionic acid amide, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amide and related compounds | |
RU2005123390A (en) | NEW Ethylenediamine Derivatives | |
KR910018374A (en) | Heterocycle substituted cycloalkano [b] dihydroindoles and -indolesulfonamides | |
EP1692121A1 (en) | Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof | |
JPWO2021055621A5 (en) | ||
JPWO2020051424A5 (en) | ||
RU2005136431A (en) | 4-, 6-OR 7-HYDROXYINDOLES WITH N-OXIDE GROUPS AND THEIR APPLICATION AS A THERAPEUTIC | |
KR830010067A (en) | Method for preparing soluble compounds having analgesic action | |
JPWO2004052871A1 (en) | Benzomorpholine derivatives | |
KR940021532A (en) | Phenylglysanamides of Heterocyclic Substituted Phenylacetic Acid Derivatives | |
CA2405076C (en) | Dual molecules containing a peroxide derivative, synthesis and therapeutic applications thereof | |
LU81430A1 (en) | NEW CYSTAMINES | |
FR2756825A1 (en) | NEW DERIVATIVES [3H] -BENZOXAZOLE-2-THIONES AND [3H] - BENZOTHIAZOLE-2-THIONES SUBSTITUTES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |